First-in-human experience from RESET-AF (Rapid onE-Shot Electroporation Trial for Atrial Fibrillation)

{"BACKGROUND":[0],"AND":[1],"AIMS:":[2],",":[3],"CRC":[4],"EP,":[5],"Tustin,":[6],"CA,":[7],"USA),":[8],"trial":[9],"registration":[10],"ACTRN12622001523796":[11],"(Date":[12],"registered":[13],"8th":[14],"December":[15],"2022).":[16],"METHODS:":[17],"In":[18],"36":[19],"consecutively-enrolled":[20],"patients":[21,54],"(57":[22],"±":[23],"11":[24],"years,":[25],"69%":[26],"male)":[27],"with":[28,72,144,147,163],"symptomatic":[29],"paroxysmal":[30,229],"(n":[31,36],"=":[32,37],"22)":[33],"and":[34,69,77,82,96,103,119,180,206,212,230,237],"persistent":[35,231],"14)":[38],"AF,":[39],"pulmonary":[40],"vein":[41],"isolation":[42],"(PVI)":[43],"was":[44,137,156,194],"performed":[45],"using":[46],"this":[47],"catheter,":[48],"guided":[49],"by":[50],"3D":[51],"mapping.":[52],"All":[53,127],"underwent":[55],"remapping":[56],"at":[57,67,91,101,160,210],"3":[58,197],"months":[59,71,93,162,214],"to":[60,158],"confirm":[61],"PVI":[62,115,179,204],"durability.":[63],"Patients":[64],"were":[65,129,176],"followed":[66],"6":[68,211],"12":[70,92,161,213],"clinical":[73,239],"review,":[74],"Holter":[75],"monitoring":[76],"electrocardiography.":[78],"The":[79,109,172,199],"primary":[80,165,236],"efficacy":[81,111,166,174],"safety":[83],"endpoints":[84,112,128,175],"included":[85,113],"a":[86,148,164,221],"freedom":[87,121,185,207],"from":[88,122,186,208],"recurrent":[89],"AF":[90,123,209,232],">":[94,117,124],"50%":[95,118],"serious":[97],"adverse":[98],"events":[99],"(SAE)":[100],"7":[102],"30":[104],"days":[105],"<":[106],"5%,":[107],"respectively.":[108],"secondary":[110,173,238],"3-month":[114,178],"durability":[116,205],"6-month":[120,184],"60%.":[125],"RESULTS:":[126],"achieved":[130,233],"in":[131,196],"the":[132,189,191],"entire":[133],"study":[134,219],"cohort.":[135],"There":[136],"1":[138],"SAE":[139,150],"(renal":[140],"impairment":[141],"which":[142],"resolved":[143],"conservative":[145],"management)":[146],"total":[149],"rate":[151],"of":[152,168,220,228],"2.8%.":[153],"One":[154],"patient":[155],"lost":[157],"follow-up":[159],"endpoint":[167],"92%":[169],"(32/35":[170],"patients).":[171],"82%":[177],"94%":[181],"(34/36":[182],"patients)":[183],"AF.":[187],"During":[188],"study,":[190],"PFA":[192,223],"dose":[193],"adjusted":[195],"cohorts.":[198],"\\"optimized":[200],"subset\\"":[201],"had":[202],"100%":[203],"without":[215],"SAEs.":[216],"CONCLUSION:":[217],"This":[218],"novel":[222],"catheter":[224],"system":[225],"for":[226],"ablation":[227],"all":[234],"predetermined":[235],"endpoints.":[240]}